Screening for Pancreatic Cancer

US Preventive Services Task Force Reaffirmation Recommendation Statement

Douglas K. Owens, Karina W. Davidson, Alex H. Krist, Michael J. Barry, Michael Cabana, Aaron Caughey, Susan J. Curry, Chyke A. Doubeni, John W. Epling, Martha Kubik, C. Seth Landefeld, Carol M. Mangione, Lori Pbert, Michael Silverstein, Melissa A. Simon, Chien Wen Tseng, John B. Wong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Importance: Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100000 person-years. However, the death rate is 11.0 deaths per 100000 person-years because the prognosis of pancreatic cancer is poor. Although its incidence is low, pancreatic cancer is the third most common cause of cancer death in the United States. Because of the increasing incidence of pancreatic cancer, along with improvements in early detection and treatment of other types of cancer, it is estimated that pancreatic cancer may soon become the second-leading cause of cancer death in the United States. Objective: To update the 2004 US Preventive Services Task Force (USPSTF) recommendation on screening for pancreatic cancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of screening for pancreatic cancer, the diagnostic accuracy of screening tests for pancreatic cancer, and the benefits and harms of treatment of screen-detected or asymptomatic pancreatic cancer. Findings: The USPSTF found no evidence that screening for pancreatic cancer or treatment of screen-detected pancreatic cancer improves disease-specific morbidity or mortality, or all-cause mortality. The USPSTF found adequate evidence that the magnitude of the benefits of screening for pancreatic cancer in asymptomatic adults can be bounded as no greater than small. The USPSTF found adequate evidence that the magnitude of the harms of screening for pancreatic cancer and treatment of screen-detected pancreatic cancer can be bounded as at least moderate. The USPSTF reaffirms its previous conclusion that the potential benefits of screening for pancreatic cancer in asymptomatic adults do not outweigh the potential harms. Conclusions and Recommendation: The USPSTF recommends against screening for pancreatic cancer in asymptomatic adults. (D recommendation).

Original languageEnglish (US)
Pages (from-to)438-444
Number of pages7
JournalJAMA - Journal of the American Medical Association
Volume322
Issue number5
DOIs
StatePublished - Aug 6 2019

Fingerprint

Advisory Committees
Pancreatic Neoplasms
Mortality
Cause of Death
Neoplasms
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Screening for Pancreatic Cancer : US Preventive Services Task Force Reaffirmation Recommendation Statement. / Owens, Douglas K.; Davidson, Karina W.; Krist, Alex H.; Barry, Michael J.; Cabana, Michael; Caughey, Aaron; Curry, Susan J.; Doubeni, Chyke A.; Epling, John W.; Kubik, Martha; Landefeld, C. Seth; Mangione, Carol M.; Pbert, Lori; Silverstein, Michael; Simon, Melissa A.; Tseng, Chien Wen; Wong, John B.

In: JAMA - Journal of the American Medical Association, Vol. 322, No. 5, 06.08.2019, p. 438-444.

Research output: Contribution to journalArticle

Owens, DK, Davidson, KW, Krist, AH, Barry, MJ, Cabana, M, Caughey, A, Curry, SJ, Doubeni, CA, Epling, JW, Kubik, M, Landefeld, CS, Mangione, CM, Pbert, L, Silverstein, M, Simon, MA, Tseng, CW & Wong, JB 2019, 'Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement', JAMA - Journal of the American Medical Association, vol. 322, no. 5, pp. 438-444. https://doi.org/10.1001/jama.2019.10232
Owens, Douglas K. ; Davidson, Karina W. ; Krist, Alex H. ; Barry, Michael J. ; Cabana, Michael ; Caughey, Aaron ; Curry, Susan J. ; Doubeni, Chyke A. ; Epling, John W. ; Kubik, Martha ; Landefeld, C. Seth ; Mangione, Carol M. ; Pbert, Lori ; Silverstein, Michael ; Simon, Melissa A. ; Tseng, Chien Wen ; Wong, John B. / Screening for Pancreatic Cancer : US Preventive Services Task Force Reaffirmation Recommendation Statement. In: JAMA - Journal of the American Medical Association. 2019 ; Vol. 322, No. 5. pp. 438-444.
@article{c631209cd1fa4d08a21459b80898482c,
title = "Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement",
abstract = "Importance: Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100000 person-years. However, the death rate is 11.0 deaths per 100000 person-years because the prognosis of pancreatic cancer is poor. Although its incidence is low, pancreatic cancer is the third most common cause of cancer death in the United States. Because of the increasing incidence of pancreatic cancer, along with improvements in early detection and treatment of other types of cancer, it is estimated that pancreatic cancer may soon become the second-leading cause of cancer death in the United States. Objective: To update the 2004 US Preventive Services Task Force (USPSTF) recommendation on screening for pancreatic cancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of screening for pancreatic cancer, the diagnostic accuracy of screening tests for pancreatic cancer, and the benefits and harms of treatment of screen-detected or asymptomatic pancreatic cancer. Findings: The USPSTF found no evidence that screening for pancreatic cancer or treatment of screen-detected pancreatic cancer improves disease-specific morbidity or mortality, or all-cause mortality. The USPSTF found adequate evidence that the magnitude of the benefits of screening for pancreatic cancer in asymptomatic adults can be bounded as no greater than small. The USPSTF found adequate evidence that the magnitude of the harms of screening for pancreatic cancer and treatment of screen-detected pancreatic cancer can be bounded as at least moderate. The USPSTF reaffirms its previous conclusion that the potential benefits of screening for pancreatic cancer in asymptomatic adults do not outweigh the potential harms. Conclusions and Recommendation: The USPSTF recommends against screening for pancreatic cancer in asymptomatic adults. (D recommendation).",
author = "Owens, {Douglas K.} and Davidson, {Karina W.} and Krist, {Alex H.} and Barry, {Michael J.} and Michael Cabana and Aaron Caughey and Curry, {Susan J.} and Doubeni, {Chyke A.} and Epling, {John W.} and Martha Kubik and Landefeld, {C. Seth} and Mangione, {Carol M.} and Lori Pbert and Michael Silverstein and Simon, {Melissa A.} and Tseng, {Chien Wen} and Wong, {John B.}",
year = "2019",
month = "8",
day = "6",
doi = "10.1001/jama.2019.10232",
language = "English (US)",
volume = "322",
pages = "438--444",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Screening for Pancreatic Cancer

T2 - US Preventive Services Task Force Reaffirmation Recommendation Statement

AU - Owens, Douglas K.

AU - Davidson, Karina W.

AU - Krist, Alex H.

AU - Barry, Michael J.

AU - Cabana, Michael

AU - Caughey, Aaron

AU - Curry, Susan J.

AU - Doubeni, Chyke A.

AU - Epling, John W.

AU - Kubik, Martha

AU - Landefeld, C. Seth

AU - Mangione, Carol M.

AU - Pbert, Lori

AU - Silverstein, Michael

AU - Simon, Melissa A.

AU - Tseng, Chien Wen

AU - Wong, John B.

PY - 2019/8/6

Y1 - 2019/8/6

N2 - Importance: Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100000 person-years. However, the death rate is 11.0 deaths per 100000 person-years because the prognosis of pancreatic cancer is poor. Although its incidence is low, pancreatic cancer is the third most common cause of cancer death in the United States. Because of the increasing incidence of pancreatic cancer, along with improvements in early detection and treatment of other types of cancer, it is estimated that pancreatic cancer may soon become the second-leading cause of cancer death in the United States. Objective: To update the 2004 US Preventive Services Task Force (USPSTF) recommendation on screening for pancreatic cancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of screening for pancreatic cancer, the diagnostic accuracy of screening tests for pancreatic cancer, and the benefits and harms of treatment of screen-detected or asymptomatic pancreatic cancer. Findings: The USPSTF found no evidence that screening for pancreatic cancer or treatment of screen-detected pancreatic cancer improves disease-specific morbidity or mortality, or all-cause mortality. The USPSTF found adequate evidence that the magnitude of the benefits of screening for pancreatic cancer in asymptomatic adults can be bounded as no greater than small. The USPSTF found adequate evidence that the magnitude of the harms of screening for pancreatic cancer and treatment of screen-detected pancreatic cancer can be bounded as at least moderate. The USPSTF reaffirms its previous conclusion that the potential benefits of screening for pancreatic cancer in asymptomatic adults do not outweigh the potential harms. Conclusions and Recommendation: The USPSTF recommends against screening for pancreatic cancer in asymptomatic adults. (D recommendation).

AB - Importance: Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100000 person-years. However, the death rate is 11.0 deaths per 100000 person-years because the prognosis of pancreatic cancer is poor. Although its incidence is low, pancreatic cancer is the third most common cause of cancer death in the United States. Because of the increasing incidence of pancreatic cancer, along with improvements in early detection and treatment of other types of cancer, it is estimated that pancreatic cancer may soon become the second-leading cause of cancer death in the United States. Objective: To update the 2004 US Preventive Services Task Force (USPSTF) recommendation on screening for pancreatic cancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of screening for pancreatic cancer, the diagnostic accuracy of screening tests for pancreatic cancer, and the benefits and harms of treatment of screen-detected or asymptomatic pancreatic cancer. Findings: The USPSTF found no evidence that screening for pancreatic cancer or treatment of screen-detected pancreatic cancer improves disease-specific morbidity or mortality, or all-cause mortality. The USPSTF found adequate evidence that the magnitude of the benefits of screening for pancreatic cancer in asymptomatic adults can be bounded as no greater than small. The USPSTF found adequate evidence that the magnitude of the harms of screening for pancreatic cancer and treatment of screen-detected pancreatic cancer can be bounded as at least moderate. The USPSTF reaffirms its previous conclusion that the potential benefits of screening for pancreatic cancer in asymptomatic adults do not outweigh the potential harms. Conclusions and Recommendation: The USPSTF recommends against screening for pancreatic cancer in asymptomatic adults. (D recommendation).

UR - http://www.scopus.com/inward/record.url?scp=85070110853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070110853&partnerID=8YFLogxK

U2 - 10.1001/jama.2019.10232

DO - 10.1001/jama.2019.10232

M3 - Article

VL - 322

SP - 438

EP - 444

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 5

ER -